164 related articles for article (PubMed ID: 11555513)
1. Unexplained pulmonary hypertension in chronic myeloproliferative disorders.
Dingli D; Utz JP; Krowka MJ; Oberg AL; Tefferi A
Chest; 2001 Sep; 120(3):801-8. PubMed ID: 11555513
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases.
García-Manero G; Schuster SJ; Patrick H; Martinez J
Am J Hematol; 1999 Feb; 60(2):130-5. PubMed ID: 9929105
[TBL] [Abstract][Full Text] [Related]
3. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders.
Gupta R; Perumandla S; Patsiornik Y; Niranjan S; Ohri A
J Natl Med Assoc; 2006 Nov; 98(11):1779-82. PubMed ID: 17128687
[TBL] [Abstract][Full Text] [Related]
4. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders.
Fruchtman SM; Petitt RM; Gilbert HS; Fiddler G; Lyne A;
Leuk Res; 2005 May; 29(5):481-91. PubMed ID: 15755500
[TBL] [Abstract][Full Text] [Related]
5. Uncontrolled thrombocytosis in chronic myeloproliferative disorders.
Kessler CM; Klein HG; Havlik RJ
Br J Haematol; 1982 Jan; 50(1):157-67. PubMed ID: 6976793
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases.
Guilpain P; Montani D; Damaj G; Achouh L; Lefrère F; Le Pavec J; Marfaing-Koka A; Dartevelle P; Simonneau G; Humbert M; Hermine O
Respiration; 2008; 76(3):295-302. PubMed ID: 18160817
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis.
Altintas A; Karahan Z; Pasa S; Cil T; Boyraz T; Iltumur K; Ayyildiz O
Leuk Lymphoma; 2007 Oct; 48(10):1981-7. PubMed ID: 17852711
[TBL] [Abstract][Full Text] [Related]
8. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors of high echocardiographic probability of pulmonary hypertension in myeloproliferative neoplasms patients.
Jindamai Y; Rattarittamrong E; Phrommintikul A; Yongsmith L; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Int J Hematol; 2020 Nov; 112(5):631-639. PubMed ID: 32700192
[TBL] [Abstract][Full Text] [Related]
10. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
11. Cardiac involvement in patients with myeloproliferative disorders.
Reisner SA; Rinkevich D; Markiewicz W; Tatarsky I; Brenner B
Am J Med; 1992 Nov; 93(5):498-504. PubMed ID: 1442851
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders.
Birgegård G; Björkholm M; Kutti J; Lärfars G; Löfvenberg E; Markevärn B; Merup M; Palmblad J; Mauritzson N; Westin J; Samuelsson J
Haematologica; 2004 May; 89(5):520-7. PubMed ID: 15136214
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors for Pulmonary Hypertension associated with chronic Myeloproliferative Neoplasms.
Ferrari A; Scandura J; Masciulli A; Krichevsky S; Gavazzi A; Barbui T
Eur J Haematol; 2021 Feb; 106(2):250-259. PubMed ID: 33135220
[TBL] [Abstract][Full Text] [Related]
14. Frequency and etiology of pulmonary hypertension in patients with myeloproliferative neoplasms.
Brabrand M; Hansen KN; Laursen CB; Larsen TS; Vestergaard H; Abildgaard N
Eur J Haematol; 2019 Mar; 102(3):227-234. PubMed ID: 30450659
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients.
Thiele J; Kvasnicka HM
Ann Hematol; 2003 Mar; 82(3):148-52. PubMed ID: 12634946
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary hypertension in patients with myeloproliferative neoplasms: A large cohort of 183 patients.
Venton G; Turcanu M; Colle J; Thuny F; Chebrek S; Farnault L; Mercier C; Ivanov V; Fanciullino R; Suchon P; Jarrot PA; Aissi K; Roche P; Cautela J; Arcani R; Costello R
Eur J Intern Med; 2019 Oct; 68():71-75. PubMed ID: 31421946
[TBL] [Abstract][Full Text] [Related]
17. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
[No Abstract] [Full Text] [Related]
18. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
19. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
20. Familial chronic myeloproliferative disorders: the state of the art.
Rumi E
Hematol Oncol; 2008 Sep; 26(3):131-8. PubMed ID: 18484677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
